MedPath

Clinical Trial News

RINVOQ (Upadacitinib) Demonstrates Efficacy in Atopic Dermatitis with Head and Neck Involvement: Phase III Trial Analysis

  • A post-hoc analysis of Phase III trials Measure Up 1 and Measure Up 2 showed RINVOQ's efficacy in treating moderate-to-severe atopic dermatitis (AD).
  • Upadacitinib demonstrated significant skin clearance in the head and neck region, reduced itch, and improved quality of life compared to placebo at week 16.
  • The analysis stratified patients by the severity of head and neck involvement, showing consistent benefits across varying degrees of AD severity.
  • RINVOQ, a selective JAK inhibitor, is being investigated for various immune-mediated inflammatory diseases, expanding its potential therapeutic applications.

Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)

NCT03569293Active, Not RecruitingPhase 3
AbbVie
Posted 8/13/2018

A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)

NCT03607422Active, Not RecruitingPhase 3
AbbVie
Posted 7/27/2018

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

NCT05843643RecruitingPhase 3
AbbVie
Posted 7/19/2023

A study to assess adverse events and effectiveness of upadacitinib oral tablets in adult and adolescent participants with vitiligo.

2023-506195-27-00Active, Not RecruitingPhase 3
AbbVie Deutschland GmbH & Co. KG
Posted 12/19/2023

A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis

NCT03725202CompletedPhase 3
AbbVie
Posted 2/6/2019

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

NCT05889182RecruitingPhase 3
AbbVie
Posted 6/21/2023

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

NCT06012240Active, Not RecruitingPhase 3
AbbVie
Posted 10/11/2023

A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)

NCT04161898Active, Not RecruitingPhase 3
AbbVie
Posted 2/4/2020

Donanemab Approval Under Scrutiny: Concerns Raised Over Safety, Efficacy, and Conflicts of Interest

  • An investigation raises concerns about the safety and efficacy of donanemab, a newly approved Alzheimer's drug, citing patient deaths and adverse events during trials.
  • Financial ties between FDA advisory committee members and the drug's manufacturer, Eli Lilly, and other related companies are under scrutiny for potential conflicts of interest.
  • The FDA's initial rejection of donanemab due to missing data and safety concerns, followed by its approval after additional data collection, raises questions about the drug's evaluation process.
  • Claims of donanemab's effectiveness in slowing Alzheimer's progression are being challenged, with experts pointing to misleading use of relative differences in cognitive decline.

Sam Neill Credits Breakthrough Drug for Remission from Angioimmunoblastic T-Cell Lymphoma

  • Sam Neill, the actor known for his role in Jurassic Park, is in remission from stage three angioimmunoblastic T-cell lymphoma thanks to a new anti-cancer drug.
  • Diagnosed in 2022, Neill's initial chemotherapy proved ineffective, leading to the adoption of a novel treatment that has significantly improved his prognosis.
  • Neill attends treatment once a month and remains grateful for medical advancements, acknowledging he might not have survived if diagnosed two decades prior.
  • Despite the drug's potential for limited long-term efficacy, Neill maintains a positive outlook, focusing on his work and overall well-being.

Minimally Invasive Laser Therapy Shows Promise for Drug-Resistant Epilepsy

  • A study published in Annals of Neurology highlights the effectiveness of magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) for drug-resistant epilepsy caused by periventricular nodular heterotopia (PNVH).
  • The MRgLITT procedure precisely targets and destroys abnormal brain tissues responsible for seizures, guided by detailed brain mapping using stereo-electroencephalography (SEEG).
  • Results showed that up to 80% of patients with localized abnormal brain tissue became seizure-free after the SEEG-guided MRgLITT procedure, offering a life-changing option.
  • This minimally invasive approach offers a potential game-changer for individuals struggling with medication-resistant epilepsy, avoiding more invasive brain surgeries.

2Seventy Bio Halts Abecma Trial Amid Evolving Multiple Myeloma Treatment Landscape

• 2Seventy Bio has stopped enrolling patients in the Phase 3 KarMMa-9 study evaluating Abecma in newly diagnosed multiple myeloma patients with suboptimal responses to stem cell transplants. • The decision aims to save $80 million and help 2Seventy Bio achieve financial breakeven next year, following a $27 million operating loss in the second quarter. • The discontinuation was influenced by the improved treatment landscape for newly diagnosed multiple myeloma, resulting in fewer eligible patients for the study. • Abecma, co-developed with Bristol Myers Squibb, remains available for later-line treatment of multiple myeloma, with 2Seventy Bio projecting continued revenue growth.

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

NCT06413498RecruitingPhase 3
Kite, A Gilead Company
Posted 8/23/2024

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

NCT06045806Active, Not RecruitingPhase 3
Celgene
Posted 10/16/2023

Ziresovir Shows Promise in Reducing RSV Bronchiolitis Severity in Infants

  • A Phase 3 trial in China found that ziresovir significantly improved clinical outcomes in infants hospitalized with respiratory syncytial virus (RSV).
  • Ziresovir led to a greater reduction in the Wang bronchiolitis clinical score and RSV viral load compared to placebo.
  • Adverse events were comparable between the ziresovir and placebo groups, with diarrhea, elevated liver enzyme levels, and rash being the most common.
  • The study suggests ziresovir could be an effective therapeutic option for RSV in young children, warranting further international trials.

Viral Inhibition in Children for Treatment of RSV

NCT02654171CompletedPhase 2
Shanghai Ark Biopharmaceutical Co., Ltd.
Posted 5/27/2016

A Study of AK0529 in Chinese Infants Hospitalized With RSV

NCT04231968CompletedPhase 3
Shanghai Ark Biopharmaceutical Co., Ltd.
Posted 9/22/2020

Topical Ruxolitinib Reshapes Vitiligo Treatment Landscape After FDA Approval

  • Topical ruxolitinib has gained FDA approval, marking a significant advancement in vitiligo treatment and offering a new management strategy.
  • The approval of topical ruxolitinib provides a targeted approach to address the underlying pathophysiology of vitiligo.
  • Clinical trials have demonstrated the efficacy of topical ruxolitinib in repigmenting vitiliginous skin, offering hope for improved cosmetic outcomes.
  • Experts emphasize the importance of integrating topical ruxolitinib into comprehensive vitiligo management plans for optimal patient care.

UAB Launches Clinical Trial Evaluating Novel Therapy for Type 2 Diabetes

  • The University of Alabama at Birmingham (UAB) is conducting a clinical trial, TRANSCEND-T2D-2, to assess a new investigational medicine for type 2 diabetes.
  • The study aims to determine the efficacy of the investigational medicine in managing blood glucose levels and weight compared to existing treatments.
  • Eligible participants include adults aged 18 or older with type 2 diabetes, a BMI of 25 or higher, and HbA1c levels between 7.0% and 10.5%.
  • The trial requires participants to have been taking at least 1500mg of metformin daily for a minimum of three months, with or without an SGLT2i.

Polatuzumab Vedotin Plus R-CHP Shows Promise in High-Risk DLBCL

  • A phase III trial evaluated polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) versus R-CHOEP in younger patients with high-risk diffuse large B-cell lymphoma (DLBCL).
  • The study aimed to determine if Pola-R-CHP could improve outcomes compared to the standard R-CHOEP regimen in this patient population.
  • Results indicated that Pola-R-CHP could be a viable alternative to R-CHOEP, offering a potentially less toxic yet effective treatment option for high-risk DLBCL.
  • Further research is warranted to fully elucidate the long-term benefits and optimal use of Pola-R-CHP in DLBCL treatment.

Sam Neill Credits Experimental Drug for Remission from Angioimmunoblastic T-cell Lymphoma

  • Actor Sam Neill is in remission from stage 3 angioimmunoblastic T-cell lymphoma after an experimental drug proved effective following unsuccessful chemotherapy.
  • Diagnosed in 2022, Neill receives the treatment monthly, a reduced frequency from the initial regimen, and acknowledges its eventual loss of efficacy.
  • Neill expresses gratitude for advancements in cancer treatment, stating he might not be alive today if diagnosed 20 years ago, highlighting the drug's impact.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.